Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Currency in USD	2025
Operating Income	473.80 Million
Income Before Tax	339.50 Million
Income Tax Expense	92.40 Million
Net Income	247.10 Million
Eps	3.51
Epsdiluted	3.48
Weighted Average Shs Out	70.35 Million
Weighted Average Shs Out Dil	71.89 Million
Research And Development Expenses	301.10 Million
Selling General And Administrative Expenses	1.17 Billion
Depreciation And Amortization	90.40 Million
Interest Expense	59.40 Million
Interest Income	N/A
Net Interest Income	N/A
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	1.94 Billion
Ebitda	564.20 Million

Insulet Corporation Annual Reports (10-K)